Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997–2012)

Wouda, Raelene M.; Miller, Mairin; Chon, Esther; Stein, Timothy J.

doi:10.2460/javma.246.11.1230

Cited by 37 publications

(45 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…, Wouda et al . ). Although canine primary pulmonary HS has not been well documented, a site predilection for the right middle and left cranial lung lobes has been suggested (Tsai et al .…”

Section: Discussionmentioning

confidence: 97%

“…Interestingly, two miniature schnauzers previously identified in the literature were also discovered to have primary pulmonary lesions via personal communication with the corresponding authors (Cannon et al . 2015, Wouda et al . 2015.…”

Section: Discussionmentioning

confidence: 99%

“…, Wouda et al . ). The purpose of this retrospective study is to describe a series of miniature schnauzers diagnosed with HS, assess for over‐representation of the breed compared to the overall hospital population, and to evaluate pedigrees for common ancestors.…”

Section: Introductionmentioning

confidence: 97%

See 2 more Smart Citations

Histiocytic sarcoma in 14 miniature schnauzers – a new breed predisposition?

Lenz

Furrow

Craig

et al. 2017

J of Small Animal Practice

View full text Add to dashboard Cite

Objectives To describe a series of miniature schnauzers diagnosed with histiocytic sarcoma and assess for possible breed predisposition. Materials and Methods Medical records of miniature schnauzers with a diagnosis of histiocytic sarcoma between January 2008 and April 2015 were reviewed. Data collected included signalment, body weight, presenting complaint, date of diagnosis, clinicopathologic and diagnostic imaging findings, treatment, therapeutic response, date of death or last follow-up and necropsy findings. Breed predisposition was assessed with odds ratios, using breed-matched dogs without histiocytic sarcoma admitted during the study period as controls. Pedigree analysis was performed for dogs with available registration information. Results Fourteen miniature schnauzers were diagnosed with histiocytic sarcoma during the study period, making them over-represented among the hospital population (odds ratio=4.8, P=0.0009). Disease was considered localised in ten dogs and disseminated in four. Of the dogs with localised disease, nine were diagnosed with primary pulmonary histiocytic sarcoma based on the presence of a large pulmonary mass with (n=7) or without (n=2) evidence of intra-thoracic metastasis, and one had gastric histiocytic sarcoma with nodal metastasis. Treatments varied, but an aggressive clinical course was found in most patients. Pedigree analysis revealed a recent common ancestor for a subset of the dogs assessed. Clinical Significance Miniature schnauzers were over-represented among dogs with histiocytic sarcoma in this patient population. Pedigree analysis supports an inherited risk factor, which has not previously been suggested in the breed. Primary pulmonary involvement with or without intra-thoracic metastasis was common in this cohort.

show abstract

“…, Wouda et al . ). Although canine primary pulmonary HS has not been well documented, a site predilection for the right middle and left cranial lung lobes has been suggested (Tsai et al .…”

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Histiocytic sarcoma in 14 miniature schnauzers – a new breed predisposition?

Lenz

Furrow

Craig

et al. 2017

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

“…In the disseminated form of the disease, palliative treatment and concurrent use of steroids have been identified as negative prognostic factors. 2,3,8,12,17,18 It is currently unknown if patients with localized PHS experience comparable survival times to other localized forms of the disease. The primary aim of this study was to describe clinical characteristics, characterize prognostic factors and report outcome of a larger group of dogs with primary PHS.…”

Section: Introductionmentioning

confidence: 99%

Primary pulmonary histiocytic sarcoma in dogs: A retrospective analysis of 37 cases (2000‐2015)

Marlowe

Robat²,

Clarke

et al. 2018

Vet Comparative Oncology

View full text Add to dashboard Cite

Primary pulmonary histiocytic sarcoma (PHS) has been reported, but is not well characterized. The aim of this retrospective study was to describe clinical characteristics, characterize prognostic factors and report the outcome of a larger group of dogs with primary PHS. Medical records of dogs diagnosed with primary PHS at 11 institutions were retrospectively reviewed. Thirty‐seven dogs were included; 13 received CCNU‐based chemotherapy alone, 18 received surgery and adjuvant CCNU‐based chemotherapy, 3 received medical management alone and 3 dogs received surgery alone. The overall median progression free survival (PFS) and the median survival (overall survival [OS]) were 197 and 237 days, respectively. Measurable responses were noted in dogs receiving only chemotherapy; however, responses were not durable with PFS (91 days) and OS times (131 days) shorter than overall medians. Dogs that received surgery and chemotherapy had significantly prolonged PFS (276 days, P = 0.001) and OS (374 days, P = 0.001), compared with dogs not receiving surgery. As only three dogs undergoing surgery did not receive chemotherapy, it is not possible to determine the contribution of chemotherapy as an adjuvant to surgery. Dogs without evidence of intra‐thoracic metastatic disease were much more likely to undergo surgery (odds ratio = 7.04; P = 0.018). While the presence of metastasis or clinical signs at diagnosis negatively impacted PFS, only the former negatively impacted OS. These data imply that dogs presenting with PHS amenable to surgery (ie, no clinical evidence of metastasis) benefit from surgical intervention; however, the lack of a comparable surgery alone group precludes assessment of the efficacy of post‐surgical adjuvant chemotherapy.

show abstract

“…Studies of dogs with metastatic osteosarcoma (OSA) treated with a variety of different therapeutic protocols including chemotherapy and/or radiation therapy yielded median survival times between 61 and 95 days . Response rates to chemotherapeutics in dogs with pulmonary metastases from solid tumours are typically below 30% . These studies illustrate the need for development of therapeutic agents that can enhance the activity, without increasing toxicity, of established therapeutic protocols.…”

Section: Introductionmentioning

confidence: 99%

In vitro and in vivo activity of liposome‐encapsulated curcumin for naturally occurring canine cancers

Withers

York

Johnson

et al. 2018

Vet Comparative Oncology

View full text Add to dashboard Cite

Curcumin has well-established anti-cancer properties in vitro, however, its therapeutic potential has been hindered by its poor bioavailability. Lipocurc is a proprietary liposome-encapsulated curcumin formulation that enables intravenous delivery and has been shown to reach its highest concentration within lung tissue. The goal of this study was to characterize the anti-cancer and anti-angiogenic activity of Lipocurc in vitro, in addition to evaluating Lipocurc infusions in dogs with naturally occurring cancer. We therefore evaluated the effect of Lipocurc, relative to free curcumin, on the viability of canine osteosarcoma, melanoma and mammary carcinoma cell lines, as well as the ability of Lipocurc to inhibit endothelial cell viability, migration and tube formation. We also undertook a pilot clinical trial consisting of four weekly 8-hour Lipocurc infusions in 10 cancer-bearing dogs. Tumour cell proliferation was inhibited by curcumin at concentrations exceeding those achievable in the lung tissue of dogs. Similarly, equivalent high concentrations of Lipocurc and curcumin also inhibited endothelial cell viability, migration and tube formation. Four out of six dogs completing planned infusions of Lipocurc experienced stable disease; however, no radiographic responses were detected.

show abstract

Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997–2012)

Cited by 37 publications

References 22 publications

Histiocytic sarcoma in 14 miniature schnauzers – a new breed predisposition?

Histiocytic sarcoma in 14 miniature schnauzers – a new breed predisposition?

Primary pulmonary histiocytic sarcoma in dogs: A retrospective analysis of 37 cases (2000‐2015)

In vitro and in vivo activity of liposome‐encapsulated curcumin for naturally occurring canine cancers

Contact Info

Product

Resources

About